Momentum Stocks in Concentration: Ampio Pharmaceuticals, Inc. (NYSE:AMPE), Apricus Biosciences, Inc. (NASDAQ:APRI)


Ampio Pharmaceuticals, Inc. (NYSE:AMPE)

Ampio Pharmaceuticals, Inc. (NYSE:AMPE) represented a move of 1.82 percent or $-0.05 per share and closed its previous day trading session at $3.35. 992161 Shares were traded in the last trading session with an Average Volume of 1.78 Million Shares. The stock currently has a Market Capitalization of 226.49 Million.

Ampio Pharmaceuticals, Inc. develops proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation, CNS disease, and male sexual dysfunction. Principal products offered by the Company include Optina, an oral drug for the treatment of diabetic retinopathy and macular edema; and Vasaloc, an oral drug for the treatment of diabetic nephropathy. Ampio Pharmaceuticals, Inc. is based in Greenwood Village, Colorado.

The stock traded between $0.38 and $4.95 over 1-Year time period showing its price to sales ratio of 0. Ampio Pharmaceuticals, Inc. (NYSE:AMPE) is currently showing an INCREASING volatility over a period of 10-Days while the 20-Days Volatility showing a INCREASING trend.

Right now, the stock has a 50-Day Simple Moving Average of $23.14 and 200-Day Simple Moving Average of $167.33. Its Price to Free Cash Flow is 0 and Price to Book of 0.

Analyst’s recommended the stock as 0 where 1 represents Strong Buy and 5 represents Sell.

Apricus Biosciences, Inc. (NASDAQ:APRI)

In the last trading session, Apricus Biosciences, Inc. (NASDAQ:APRI) added its value by 1.83% closing at the price of $2.78. The stock currently has market capitalization of 41.17 Million, with average volume of 553.14 Million shares.

Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Apricus Biosciences, Inc. (NASDAQ:APRI) is showing beta of 0.32. This particular value of beta suggests that Apricus Biosciences, Inc. (NASDAQ:APRI) has historically moved 32% for every 100% move in the benchmark, based on price level.

EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Apricus Biosciences, Inc. (NASDAQ:APRI) is at $-0.93.

The stock currently has RSI of 67.34. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.

Apricus Bio operates in the pharmaceutical industry and focuses on research and development in the area of drug delivery. Its proprietary drug delivery technology is called NexACT (r). Backed by revenue generating CRO business, Bio-Quant, Inc. and its NexMed USA subsidiary, Apricus Bio has leveraged the flexibility of its proven NexACT(r) drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes. The Company is seeking to monetize its existing product pipeline, including compounds from pre-clinical through Phase 3, currently focused on dermatology, sexual dysfunction and cancer. Apricus Bio was formerly known as NexMed, Inc and is headquartered in San Diago, California.

Apricus Biosciences, Inc. (NASDAQ:APRI) topped its 52-week high price of $3.49 on 02/17/17 and 52-Week Low Price of $0.86 on 05/25/17. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 9.63% and monthly volatility of 8.18% respectively.